List of Field Safety Notices from 24 to 28 November 2025.
Similar Posts
MHRA approves inavolisib for the treatment of breast cancer
The MHRA has today, 26 November 2025, approved inavolisib (Itovebi) for the treatment of adults with a type of breast cancer called HR-positive
Consultation on the International Council for Harmonisation Guideline E20 for adaptive clinical trial design
The MHRA is consulting with UK stakeholders to gather feedback and comments on ICH E20, a new international guideline.
Fast, Expert and Open – how the MHRA is poised to become a global leader in risk-proportionate regulation
New MHRA CEO puts safety, accelerated access and innovation at the centre of agency’s refreshed strategic direction.
Class 2 Medicines Recall: Mercury Pharmaceuticals Ltd, Paliperidone Mercury Pharma prolonged-release suspension for injection in pre-filled syringes, EL(26)A/01
Mercury Pharmaceuticals Ltd is recalling remaining stock of paliperidone pre-filled syringes as a precautionary measure due to Good Manufacturing Practice (GMP) deficiencies cited during a recent inspection at the finished product manufacturing site.
Vorasidenib approved to treat patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 16th September 2025, approved the medicine vorasidenib (Voranigo).
MHRA Safety Roundup: January 2026
Summary of the latest safety advice for medicines and medical device users
